Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

d a two-stage min-max design in which if there were at least nine responses in the first 42 patients, the trial was to continue to the second stage. On January 25, 2007, the Company announced that there had been at least nine remissions in the first stage and that the trial would therefore continue. Eighty-five patients were enrolled in order to ensure that at least 77 would be eligible for the trial and included in the full analysis set. At least 22 responses in 77 patients are required to confirm the 35% target response rate with 95% confidence. If the full analysis set includes all 85 patients, then at least 24 responses are required for confirmation of the target response rate.

Dr. Dan DeAngelo, Assistant Professor at Harvard Medical School and the Dana Farber Cancer Institute and an investigator on the trial commented, "The treatment of elderly patients with poor-risk AML represents a significant unmet medical need in clinical oncology, and it is important that we find new effective treatment options. Agents such as Cloretazine(R) (VNP40101M) have the potential to address this need."

Dr. Gary Schiller, Professor of Medicine at the UCLA Geffen School of Medicine and an investigator on the trial added, "This was a very important study for older AML patients treated here at UCLA. As a single agent therapy administered over 30 to 60 minutes, Cloretazine(R) (VNP40101M) is clearly an active agent with the potential to play an important role in the treatment of this difficult population."

On August 8, 2007, the Company announced that certain sites on the trial would remain open and continue to accrue patients to an ECG sub-study. Recent FDA/ICH guidance recommends that an electrocardiographic evaluation (QT/QTc) study be included in the clinical development of all new drugs. Normally these studies are conducted in healthy subjects so that disease factors/co- morbidities do not confound the results. As Cloretazine(R) (VNP40101M) is a cytotoxic agent w
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , September 1, 2015 ... on the basis of sectors, products & services ... globally coupled with the increasing demand of advanced ... expected to propel the growth for bioinformatics market. ... information efficiently is known as bioinformatics. Decreasing cost ...
(Date:9/1/2015)... , Aug. 31, 2015 Research and ... the "Regulatory Affairs for Support Staff (London, UK ... This two day course provides an ... drug development and has been designed specifically for those ... You will gain an overview of EU regulatory procedures ...
(Date:9/1/2015)... LONDON , September 1, 2015 - ... of GARFIELD-AF R egistry data presented ... real-world insights on the evolution of ... -   The first-ever two-year ... showcased at ESC Congress 2015 expose that all-cause death was the most frequent ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... ... 2015 , ... Georgia State University and its partners have ... stemming sexual assaults on their campuses. , The free, evidence-based survey was developed ... researchers and student affairs professionals responding to calls by the Obama Administration to ...
(Date:9/1/2015)... ... 2015 , ... Negative pressure wound therapy (NPWT) entails the ... exudates, fluid, and infectious materials to prepare the wound for healing and closure. ... canisters, etc.) is projected to expand continuously through 2021. , Rising patient and ...
(Date:9/1/2015)... ... ... The Jerry Segal Classic to benefit the patients of Magee Rehabilitation Hospital ... Lafayette Hill, PA. Over the past 26 years, the Classic, organized by the Friends ... to support patients and their families during their time at Magee Rehabilitation Hospital. ...
(Date:9/1/2015)... ... 01, 2015 , ... Royal River Natural Foods, a locally-owned independent natural health ... for 19 years and found that, among those who had a stroke, people who ... is part of the September 2015 issue of “Natural Insights for Well Being,” which ...
(Date:9/1/2015)... San Diego, CA (PRWEB) , ... September 01, 2015 , ... ... farms are just a few of the topics to be discussed at Seedstock’s 4th ... for Nov. 3-4, 2015, at UC San Diego. , In addition to keynotes ...
Breaking Medicine News(10 mins):Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 4Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 5
... SHENYANG, China, Jan. 20 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc.,(Nasdaq: ... focused on researching,developing, manufacturing and marketing biopharmaceutical products ... December 30, 2008 with the Chinese,State Food and ... label,extension for the treatment of idiopathic thrombocytopenic purpura ...
... member of the investment manager of Xmark Opportunity Fund, L.P. and Xmark Opportunity Fund, Ltd., sent the first letter below, ... 11, 2009, the second letter below, dated January 9, 2009, was sent to the Board. ... ... , ...
... 2008 Full-Year Sales of $63.7 Billion increased 4.3%; Full-Year ... 4.9%; EPS was $0.97Excluding Special Items, 2008 Full-Year EPS ... was $0.94, an increase of 6.8%* , NEW BRUNSWICK, ... sales for the year 2008 of $63.7 billion, an ...
... Microsoft Executives to Head Life Sciences and Shanghai Business Units ... ... CSOFT International Ltd. , a leading provider of multilingual localization, testing ... hiring of Mr. Uwe Muegge and Mr. Hirotoshi "Jerry" Ono as ...
... ... Wayne, New Jersey (PRWEB) January 20, 2009 -- ... increases in new accounts and overall usage of it,s automated conference ... more companies more reason to look for cost cutting measures. ...
... adverts in UK magazines, researchers found them filled with ... articles were trying to put across. , "Nearly ... we found the food adverts were for products high ... as ready meals, sauces and confectionary," explains Dr Jean ...
Cached Medicine News:Health News:3SBio Inc. Files for SFDA Approval for TPIAO Label Extension for the Treatment of ITP 2Health News:3SBio Inc. Files for SFDA Approval for TPIAO Label Extension for the Treatment of ITP 3Health News:3SBio Inc. Files for SFDA Approval for TPIAO Label Extension for the Treatment of ITP 4Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 2Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 3Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 4Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 5Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 6Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 7Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 8Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 9Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 2Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 3Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 4Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 5Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 6Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 7Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 8Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 9Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 10Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 11Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 12Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 13Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 14Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 15Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 16Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 17Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 18Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 19Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 20Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 21Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 22Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 23Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 24Health News:CSOFT Broadens Globalization Services in U.S. and Japan with Two New Hires 2
... the newest and most advanced automated immunoassay ... AIA-1800 launches with a full menu of ... reproductive, cardiac, and anemia assays. ,The AIA-1800 ... primary tube sampling, auto dilution, auto pretreatment, ...
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
... Functional Vision, Quality of Vision and ... both target illumination and glare luminance ... results. Day/Night testing with/without glare and ... and all ANSI standards. All Light ...
Medicine Products: